Gastrointestinale Beschwerden unter Apremilast

[1]  K. Peris,et al.  Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.

[2]  E. Lespessailles,et al.  AB0785 Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 patients with psoriatic arthritis in 3 large, phase iii, long-term studies , 2017 .

[3]  M. Gooderham,et al.  The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  L. Kircik,et al.  Oral Apremilast for the Treatment of Plaque Psoriasis. , 2016, The Journal of clinical and aesthetic dermatology.

[5]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[6]  G. Girolomoni,et al.  Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. , 2016, Acta dermato-venereologica.

[7]  H. Dupont,et al.  ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults , 2016, The American Journal of Gastroenterology.

[8]  A. Blokland,et al.  The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses , 2016, Behavioural Brain Research.

[9]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[10]  M. Helmrath,et al.  Drug-induced secretory diarrhea: A role for CFTR. , 2015, Pharmacological research.

[11]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[12]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[13]  A. Wells,et al.  SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4) , 2015 .

[14]  S. Suerbaum,et al.  S2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple , 2015, Zeitschrift für Gastroenterologie.

[15]  P. Malfertheiner,et al.  [S2k-guideline gastrointestinal infectious diseases and Whipple's disease]. , 2015, Zeitschrift fur Gastroenterologie.

[16]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[17]  M. Dransfield,et al.  Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. , 2014, American journal of respiratory cell and molecular biology.

[18]  M. Deninno.  Future directions in phosphodiesterase drug discovery. , 2012, Bioorganic & medicinal chemistry letters.

[19]  B. Abraham,et al.  Drug-induced, factitious, & idiopathic diarrhoea. , 2012, Best practice & research. Clinical gastroenterology.

[20]  P. Schafer.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. , 2012, Biochemical Pharmacology.

[21]  G. Schett,et al.  Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases , 2010, Therapeutic advances in musculoskeletal disease.

[22]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[23]  E. Aandahl,et al.  Localized effects of cAMP mediated by distinct routes of protein kinase A. , 2004, Physiological reviews.

[24]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[25]  P. Speelman,et al.  Guideline for the management of acute diarrhea in adults , 2002, Journal of gastroenterology and hepatology.

[26]  O. Chassany,et al.  Drug-Induced Diarrhoea , 2000, Drug safety.

[27]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[28]  N. Geyer,et al.  Rolipram in Major Depressive Disorder: Results of a Double-Blind Comparative Study with Imipramine , 1989, Pharmacopsychiatry.

[29]  T. Bayless,et al.  Effect of caffeine on the human small intestine. , 1976, Gastroenterology.